Kane Biotech
Kane Biotech is a Canadian-based biotechnology company focused on the research, development, and commercialization of products that prevent and remove microbial biofilms. Established in 2001, the company aims to improve human and animal welfare through innovative solutions to biofilm-related challenges and antimicrobial resistance. With a strong portfolio of 54 patents and patents pending, Kane Biotech is recognized as a leader in biofilm research and technology, and is listed on the TSX Venture Exchange under the symbol 'KNE' and on the OTC Markets under the symbol 'KNBIF'.
Industries
Nr. of Employees
small (1-50)
Kane Biotech
290-100 Innovation Drive, Winnipeg, Manitoba, Canada, R3T 6G2
Awards
Military Infectious Disease - Prototype Innovation Program (MID-PIP)
DispersinB the missing link in wound care - Clinical evaluation of DispersinB to treat biofilm mediated antimicrobial resistance in non-healing chronic wound infections
Funding (ceiling)
$3,077,247
Award Year
2020
Patents
Antimicrobial-antibiofilm compositions and methods of use thereof for personal care products
2023-08-15 • US-11723852-B2
View DetailsAntimicrobial-antibiofilm compositions and methods of use thereof for personal care products
2021-08-31 • US-11103433-B2
View DetailsAntimicrobial-antibiofilm compositions and methods of use thereof
2019-07-23 • US-10357470-B2
View DetailsAntimicrobial-antibiofilm compositions and methods of use thereof
2018-05-29 • US-9980497-B2
View Details
Antimicrobial-antibiofilm compositions and methods of use thereof for personal care products
2023-08-15 • US-11723852-B2
View DetailsAntimicrobial-antibiofilm compositions and methods of use thereof for personal care products
2021-08-31 • US-11103433-B2
View DetailsAntimicrobial-antibiofilm compositions and methods of use thereof
2019-07-23 • US-10357470-B2
View DetailsAntimicrobial-antibiofilm compositions and methods of use thereof
2018-05-29 • US-9980497-B2
View DetailsProducts
Enzyme-based antibiofilm formulations
A family of enzyme formulations that target PNAG to disrupt biofilm matrix and reduce bacterial adhesion; developed for wound, dermatology, veterinary and industrial applications.
Chelator and pH-modulating topical formulations
Topical compositions that use metal‑ion chelators and buffering agents to destabilize biofilms and support wound healing and consumer dermatology applications.
Thermo-reversible antimicrobial wound hydrogel (510(k)-cleared)
A temperature‑sensitive antimicrobial hydrogel that transitions from liquid to gel at lower temperatures and has received regulatory clearance in the U.S. for specified wound management indications.
Veterinary oral care formulations
Consumer-facing veterinary oral care products formulated to inhibit plaque and tartar biofilms in companion animals, offered in multiple delivery formats for pet care channels.
Dermatology scalp-care consumer products
Scalp detoxifier and shampoo formulations designed to address scalp conditions where biofilm persistence is implicated; products tested in large consumer studies.
Enzyme-based antibiofilm formulations
A family of enzyme formulations that target PNAG to disrupt biofilm matrix and reduce bacterial adhesion; developed for wound, dermatology, veterinary and industrial applications.
Chelator and pH-modulating topical formulations
Topical compositions that use metal‑ion chelators and buffering agents to destabilize biofilms and support wound healing and consumer dermatology applications.
Thermo-reversible antimicrobial wound hydrogel (510(k)-cleared)
A temperature‑sensitive antimicrobial hydrogel that transitions from liquid to gel at lower temperatures and has received regulatory clearance in the U.S. for specified wound management indications.
Veterinary oral care formulations
Consumer-facing veterinary oral care products formulated to inhibit plaque and tartar biofilms in companion animals, offered in multiple delivery formats for pet care channels.
Dermatology scalp-care consumer products
Scalp detoxifier and shampoo formulations designed to address scalp conditions where biofilm persistence is implicated; products tested in large consumer studies.
Expertise Areas
- Biofilm research and therapeutics
- Topical hydrogel formulation for wound care
- Enzyme-based antibiofilm agent development
- Veterinary oral care product development
Key Technologies
- Enzymatic PNAG polysaccharide cleavage
- Metal chelation and pH-modulation for biofilm destabilization
- Thermo-reversible gel and spray-to-gel delivery
- Combination formulations: antibiofilm + antimicrobial/antiseptic agents (e.g., PHMB)
News & Updates
Kane Biotech has announced an agreement to acquire FB Dermatology, expanding its product offerings in the dermatology sector.
The company aims to disrupt the global wound care hydrogel market with its first FDA cleared medical device and announces new partnerships.
An exploration of the origins of the company's name, reflecting its founder's legacy and the company's mission.
Kane Biotech has been featured in several news media articles, including BNN Bloomberg and Benzinga, highlighting its advancements in biotechnology and wound care.
Kane Biotech has announced an agreement to acquire FB Dermatology, expanding its product offerings in the dermatology sector.
The company aims to disrupt the global wound care hydrogel market with its first FDA cleared medical device and announces new partnerships.
An exploration of the origins of the company's name, reflecting its founder's legacy and the company's mission.
Kane Biotech has been featured in several news media articles, including BNN Bloomberg and Benzinga, highlighting its advancements in biotechnology and wound care.